Bristol-Myers Squibb Company
BMY · Price history
Price at last available close
$60.47
−$3.41 (-5.34%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Bristol-Myers Squibb Company
Primary reporting period: 2025-12-31 · Research updated Oct 5, 2026. A research update is not a new financial filing.
Who they are
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism.
How they make money
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, and delivers innovative medicines for patients with serious diseases. The company generates revenue primarily through the sale of pharmaceutical products across therapeutic areas including oncology, hematology, immunology, and cardiovascular disease.
Products & services
The company provides a portfolio of medicines including Eliquis, Opdivo, Revlimid, Orencia, Pomalyst, Yervoy, Reblozyl, Sprycel, Opdualag, Krazati, Augtyro, and Cobenfy.
Brands & revenue mix
Treatment for multiple myeloma.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Disclosed major customers
Customer concentration
The company reported that three major wholesalers, McKesson, Cencora, and Cardinal Health, accounted for approximately 65% of its total consolidated net revenues for the year ended December 31, 2025.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company utilizes various third-party contract manufacturers for the production of active pharmaceutical ingredients and finished drug products; specific supplier names are generally not disclosed.Source
Competitors
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
38
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
60
Fair
Financial Strength
68
Business Quality / Moat
45
Management
95
Growth Quality
28
Risk / Durability
50
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
37
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
42/100
Building Historical Record
Model Score 42/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for BMY
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can BMY maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is BMY's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is BMY's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What future growth or profitability would be needed to justify BMY's current valuation?
Essential Investment Snapshot
Wall Street Score
38
Opportunity Score
37
Market Cap
$123.56B
P/E Ratio
13.7
EPS
$4.54
52-Week High
$68.64
52-Week Low
$42.52
Beta
0.23
Intrinsic Value
$51.75
Analyst Target
$65.00
Shares Outstanding
2.04B
Total Revenue
$49.19B
Total Debt
$43.12B
Dividend
No current dividend
Liquidation Value / Share
$10.94
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on BMY.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Strong portfolio of high-growth innovative medicines.
- +Robust research and development pipeline.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Drug Manufacturers - General industry.
- −Patent expirations and loss of market exclusivity.
- −Intense competition and pricing pressures.
- −Regulatory and legal uncertainties.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
37
Sep 9, 2026
Change
+0.4
points
Current Score
38
Oct 1, 2026
Category Changes
BMY increased 0.4 points because Capital improved by 3 points.
Positive Contributors
- + Capital improved by 3 points
Projected Score
Projected Score
42
Projected Change
+4.0 points
Preliminary comparable-period financial changes suggest improvement of approximately 4.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$60.49
Model Intrinsic Value
$51.75
Difference
+$8.74
+16.9% vs IV
Margin of Safety
-16.9%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $49.19B | $48.20B | $48.30B | $45.01B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $14.68B | $13.94B | $20.87B | $19.65B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $34.51B | $34.26B | $27.43B | $25.36B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $10.72B | $9.95B | $9.78B | $9.21B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $7.41B | $7.27B | $7.87B | $7.68B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $20.61B | $20.54B | $17.77B | $16.89B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $16.67B | $15.23B | $3.17B | $19.37B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $13.90B | $13.72B | $9.66B | $8.47B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $1.73B | $1.89B | $1.95B | $1.17B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $11.91B | $9.33B | -$8.38B | $8.44B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $2.63B | $2.27B | $554.0M | $400.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $9.28B | $7.05B | -$8.95B | $8.03B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $4.54 | $3.46 | $-4.41 | $3.88 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 2.04B | 2.04B | 2.03B | 2.07B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 2.05B | 2.04B | 2.03B | 2.08B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$12.97B
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$1.62
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-15.3%
Cash Change
-30.8%
Margin Change
+14.9 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, EPS growth, debt levels, net income margin. Pressure indicators included cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 5.7%. EPS increased 153.1%. Cash declined 30.8%. Total debt declined 15.3%. Net income margin improved by 14.9 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
47
Smart Money
47
Number of Gurus
4
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Drug Manufacturers - GeneralNews
Bristol Myers (BMY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological Conditions
Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline
Rumor Mill · BMY
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial